Meeting
2023 ASCO Annual Meeting
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.
Authors
Lauren Schaff
Memorial Sloan Kettering Cancer Center, New York, NY
Lauren Schaff , John Fortunato , Christian Grommes , Igor T. Gavrilovic , Andrew Lin , Elena Pentsova , Alex Miller , Adam Newton , Ashley Gonzalez , Ingo K. Mellinghoff , Thomas Joseph Kaley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT05188508
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2087)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2087
Abstract #
TPS2087
Poster Bd #
440b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
First Author: Yoo Na Kim
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2023 ASCO Annual Meeting
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
First Author: Mansoor Raza Mirza